BCL2 and B-cell chronic lymphocytic leukemia: Another representative example is Venetoclax, a BCL-2 inhibitor approved for clinical use to treat chronic lymphocytic leukemia and certain types of small lymphocytic lymphoma [9] (Figure 1).